Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01684397 · ClinicalTrials.gov registry record · Phase 1

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

A Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by Roswell Park Cancer Institute.

Active
Registry status
Phase 1
Development phase
51
Enrollment target
5
Study locations

NCT01684397: Active Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by Roswell Park Cancer Institute.

NCT01684397 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 51 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01684397, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
51 participants
Enrollment target
5
Study locations

Study Summary

This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.

Primary Outcome

Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Bevacizumab
  • OTHER Pharmacological Study
  • DRUG Pazopanib Hydrochloride

Study Locations (5)

Kansas

  • The University of Kansas Cancer Center - Westwood

Michigan

  • Karamanos Cancer Institute - Detroit

New York

  • Roswell Park Cancer Institute - Buffalo

Pennsylvania

  • University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2012-11-21
Est. Completion 2026-08-20
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What the registry record for NCT01684397 still lists

NCT01684397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (75% lower).

The record links to 2 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01684397 lists 5 locations in 5 states (Kansas, Michigan, New York).

Frequently Asked Questions

What is clinical trial NCT01684397 about?

NCT01684397 is a clinical study titled "Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer". This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of ...

What is the current status of trial NCT01684397?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2012-11-21. Estimated completion is 2026-08-20.

What conditions does trial NCT01684397 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer.

What interventions are being tested in trial NCT01684397?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER), Pazopanib Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT01684397?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01684397 being conducted?

This trial has 5 study locations across Kansas, Michigan, New York, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01684397's enrollment target sits among peer trials

51 33rd of 45 higher than 13 of 45 other Clear Cell Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01684397, the US trial registry maintained by the National Library of Medicine. NCT01684397 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.